Key Highlights

  • Concentra Group Holdings shares are trading up 12.02% today, nearing 52-week highs.
  • Second-quarter adjusted EPS of $0.52 beat estimates by 23.81%, with revenue of $606 million topping the $591.7 million consensus.
  • The company raised full-year 2026 revenue and EBITDA guidance.
  • Concentra also announced a leadership succession plan naming President and CFO Matt DiCanio as incoming CEO.

Why Is Concentra Group Stock Rising Today?

Concentra Group Holdings (NYSE:CON) is trading sharply higher today after reporting second-quarter 2026 results that topped Wall Street estimates on both the top and bottom lines. Adjusted EPS came in at $0.52, beating the $0.42 estimate by nearly 24%, while revenue reached $606 million against a $591.7 million consensus, a beat of more than 2%. Adjusted EBITDA rose 22.5% year-over-year to $140.9 million, with margin expanding roughly 240 basis points to 23.3%.

Concentra Group Holdings is the largest provider of occupational health services in the United States by number of locations, operating approximately 628 centers across 41 states along with more than 160 onsite health clinics, serving over 50,000 patients each business day.

Leadership Succession and Raised Guidance

Alongside the earnings beat, Concentra announced a leadership transition: CEO Keith Newton will move to Executive Chairman effective November 1, 2026, with current President and CFO Matt DiCanio stepping into the CEO role. The company framed the move as a multiyear succession plan reflecting strategic continuity rather than a change in direction.

Management also raised full-year 2026 guidance, lifting the revenue range to $2.325 billion to $2.375 billion and improving adjusted EBITDA guidance, while keeping the free cash flow range of $220 million to $240 million unchanged. Several analysts raised price targets following the report, including BofA to $36 from $31 and Truist to $37 from $31, reinforcing bullish sentiment on the stock.

Conclusion

Concentra Group Holdings shares are rallying today on a combination of a strong second-quarter beat, raised full-year guidance, and a leadership succession plan that appears to have been well received by investors. The stock is now approaching its 52-week highs as it stands out as one of the strongest performers within the broader healthcare sector this earnings season.

This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.